RetiSpec develops hyperspectral imaging technology for early diagnosis of Alzheimer's disease through retinal scanning.

RetiSpec

RetiSpec is an AI-based company focused on early detection of neurodegenerative diseases through a simple eye exam. RetiSpec's proprietary AI solution leverages existing retinal imaging cameras to provide a non-invasive, accurate and scalable solution for the early detection of Alzheimer's disease. RetiSpec is involved in multiple Alzheimer's and brain health studies in leading hospitals and research networks throughout North America. 
RetiSpec is currently advancing its regulatory and market entry plans for its first clinically-validated test to predict amyloid burden at the point of care, to aid in the evaluation of individuals for Alzheimer's disease and other causes of cognitive decline. 
RetiSpec was recently selected from more than 75 global applicants to receive the Davos Alzheimer's Collaborative inaugural grant for Health System Preparedness to test its technology in optometry settings.

COM:RETISPEC

RetiSpec

Filings Not Available